The incidence and impact of thrombocytopenia in myelodysplastic syndromes.
about
Alternative agents versus prophylactic platelet transfusion for preventing bleeding in patients with thrombocytopenia due to chronic bone marrow failure: a network meta-analysis and systematic reviewThrombopoietin mimetics for patients with myelodysplastic syndromesPlatelet proteome analysis reveals integrin-dependent aggregation defects in patients with myelodysplastic syndromes.Clinical indications for thrombopoietin and thrombopoietin-receptor agonistsBeyond immune thrombocytopenia: the evolving role of thrombopoietin receptor agonists.Effect of the nonpeptide thrombopoietin receptor agonist Eltrombopag on bone marrow cells from patients with acute myeloid leukemia and myelodysplastic syndromeAntiplatelet therapy and percutaneous coronary intervention in patients with acute coronary syndrome and thrombocytopeniaThrombocytopenia in patients with myelodysplastic syndromes.Phase 2 study of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving azacitidine therapyDecitabine in myelodysplastic syndromes and chronic myelomonocytic leukemia: Argentinian/South Korean multi-institutional clinical experience.Subcutaneous or intravenous administration of romiplostim in thrombocytopenic patients with lower risk myelodysplastic syndromes.Health care utilization and mortality among elderly patients with myelodysplastic syndromes.Significance of thrombocytopenia in myelodysplastic syndromes: associations and prognostic implications.Prognostic impact of severe thrombocytopenia in low-risk myelodysplastic syndrome.Eltrombopag inhibits the proliferation of leukemia cells via reduction of intracellular iron and induction of differentiationA randomized controlled trial of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving decitabine.Analysis of the risk factors for myelosuppression after concurrent chemoradiotherapy for patients with advanced non-small cell lung cancer.Supportive care for thrombocytopenia in patients receiving treatment for myelodysplasia: a challenge for the future.A randomized, double-blind, placebo-controlled phase 2 study evaluating the efficacy and safety of romiplostim treatment of patients with low or intermediate-1 risk myelodysplastic syndrome receiving lenalidomide.The safety of thoracentesis in patients with uncorrected bleeding riskEltrombopag for the treatment of thrombocytopenia in patients with malignant and non-malignant hematologic disorders.Valproic acid for the treatment of low-risk myelodysplastic syndromes: A case report and a review of the literature.Milestones in understanding platelet production: a historical overview.Results of a randomized, double-blind study of romiplostim versus placebo in patients with low/intermediate-1-risk myelodysplastic syndrome and thrombocytopenia.A pilot phase I dose finding safety study of the thrombopoietin-receptor agonist, eltrombopag, in patients with myelodysplastic syndrome treated with azacitidine.Development and validation of a model to predict platelet response to romiplostim in patients with lower-risk myelodysplastic syndromes.Safety and efficacy of thrombopoietin-receptor agonists in myelodysplastic syndromes: a systematic review and meta-analysis of randomized controlled trials.Proteins of the mitotic checkpoint and spindle are related to chromosomal instability and unfavourable prognosis in patients with myelodysplastic syndrome.Thrombopoiesis-stimulating agents and myelodysplastic syndromes.Observational study of corrected count increments after transfusion of platelets treated with riboflavin pathogen reduction technology in additive solutions.Eltrombopag for treatment of thrombocytopenia-associated disorders.A Rare Case of Myelodysplastic Syndrome with Refractory ThrombocytopeniaThrombocytopenia in MDS: epidemiology, mechanisms, clinical consequences and novel therapeutic strategies.Effects of decitabine on megakaryocyte maturation in patients with myelodysplastic syndromes.From chronic immune thrombocytopenia to severe aplastic anemia: recent insights into the evolution of eltrombopag.Romiplostim monotherapy in thrombocytopenic patients with myelodysplastic syndromes: long-term safety and efficacy.A reciprocal role of prostate cancer on stromal DNA damage.New treatments for myelodysplastic syndromesRevised international prognostic scoring system for myelodysplastic syndromes.The effect of decitabine dose modification and myelosuppression on response and survival in patients with myelodysplastic syndromes
P2860
Q24186703-53AF5800-7621-4CE3-B269-13FE9D077DFCQ24198060-8F8129D5-24C7-42FA-B69E-CF12C1419B97Q24314265-B0D5DBC3-9B31-4300-A309-3E5371BD9FA1Q24601161-EB78F0D0-9C2D-4FBC-986A-FA8B7D70E217Q30399669-E70092EC-5BF0-4720-A088-23922DA2814CQ33385999-8E8C940D-BD04-4A29-9F4D-425944AA82FBQ33390126-1E27367F-8EEF-490E-8DC7-EB88B84E44CEQ33390639-C7D43235-D361-4145-AF8E-42A9A1E02FC3Q33390778-37221473-C13C-43E6-9C3F-7D14E0D0426DQ33392205-B4D8D53A-7CBA-42B0-A259-631CDAEAE34EQ33392293-829E0C8F-4085-4EC5-B61D-DE45151E0390Q33392602-4385ED03-42DE-4528-B6E1-F7AAFF0CB825Q33395333-262D6A90-820E-4782-A72B-89C230A017FDQ33395648-7B03B533-0FCB-48FE-BC53-343E93291E63Q33401421-5D7E2E39-B8C6-481F-9D18-0B46873BC8B9Q33402882-E7A0B6F3-A10C-48E3-84DB-07BAC5B940ACQ33403054-DEA0E439-8497-4105-84DF-C079017EEF3CQ33403765-6D588121-EC78-4AB6-AD8D-9661F3E0A50CQ33404600-96B47147-6572-43D1-93E5-6F75EEE2C4CAQ33409843-6B9AD499-0185-406E-88B9-340B224BFFACQ33411387-CEDEC698-F807-4D29-84A2-4881918958B4Q33412339-1096D594-0FE2-423D-8B8B-9C4CBB48E316Q33413326-1A6EB973-2571-4580-8429-568E5382DCAFQ33414453-CD15351F-55CA-4C3E-80D9-4B4639D03302Q33415466-9F7534A1-CEE8-40F4-8934-22133F953D8EQ33416541-7109D92C-1F3C-42E8-B3A9-B0998B7C7666Q33417304-E421F5BB-7CBE-44DA-A2B9-845758D93CE0Q33420092-1F052F85-1F9C-4150-8222-746977A7E56BQ33420207-2E2D1D60-1044-4B14-BA53-38BB3266C783Q33420599-7EC2F86B-BE68-4BE9-8D22-002CE380A6D1Q33425805-F90CF6CA-648A-45E7-9642-26E082B92DE8Q33426917-E131C7E7-B06D-464F-9800-C5429081CAF5Q33427023-F18F146C-C131-4960-AD7C-AD1E5E0C7E92Q33431466-6E1CA085-BAF1-48AC-AE12-6FF86861E2C3Q33441627-BCF64CF9-BA26-4A59-9494-746186A4AD8FQ33442715-0B01179E-03B9-482C-B8CE-AF2894FCDB57Q34000472-1885E0C1-8B6E-4975-8A87-E284DCE55CE1Q34549290-CA312F85-B598-4EAA-B96F-EE48265D6C70Q34639717-D5F0831A-21B2-4815-AB92-378E8E173D6FQ34979774-4C2590C0-D712-4C57-B2E5-BD94B5EF299C
P2860
The incidence and impact of thrombocytopenia in myelodysplastic syndromes.
description
2007 nî lūn-bûn
@nan
2007 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
The incidence and impact of thrombocytopenia in myelodysplastic syndromes.
@ast
The incidence and impact of thrombocytopenia in myelodysplastic syndromes.
@en
type
label
The incidence and impact of thrombocytopenia in myelodysplastic syndromes.
@ast
The incidence and impact of thrombocytopenia in myelodysplastic syndromes.
@en
prefLabel
The incidence and impact of thrombocytopenia in myelodysplastic syndromes.
@ast
The incidence and impact of thrombocytopenia in myelodysplastic syndromes.
@en
P2093
P2860
P50
P356
P1433
P1476
The incidence and impact of thrombocytopenia in myelodysplastic syndromes.
@en
P2093
Joseph Leveque
Mikkael A Sekeres
Robert Deuson
Roger Lyons
P2860
P304
P356
10.1002/CNCR.22602
P407
P577
2007-05-01T00:00:00Z